Key statistics
As of last trade, ProQR Therapeutics NV (0PQ:DUS) traded at 1.20, 40.13% above the 52 week low of 0.8585 set on Apr 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.20 |
|---|---|
| High | 1.20 |
| Low | 1.20 |
| Bid | 1.20 |
| Offer | 1.27 |
| Previous close | 1.25 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 105.35m |
| Free float | 83.91m |
| P/E (TTM) | -- |
| Market cap | 153.80m USD |
| EPS (TTM) | -0.4858 USD |
Data delayed at least 15 minutes, as of Feb 16 2026 08:30 GMT.
More ▼
Announcements
- ProQR Announces Planned Changes to Board Composition
- ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
- ProQR to Participate in 8th Annual Evercore Healthcare Conference
- ProQR Announces Third Quarter 2025 Operating and Financial Results
- ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
- ProQR to Participate in Upcoming Investor Conferences in October 2025
- ProQR Announces Second Quarter 2025 Operating and Financial Results
- ProQR Announces Upcoming Presentation at RNA Editing Summit
- ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
- ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
More ▼
